Therefore, in this study, CGMs were used to comprehensively evaluate blood glucose changes in patients with T2DM who were treated with premixed insulin combined with SZ-A or Met, compared to other treated with premixed insulin alone. This evidence concerns the gene INS and type 2 diabetes mellitus.